Neoadjuvant Treatment Does Not Influence PD-L1 Expression in Patients With Stage III NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
ESMO Open 2023 Aug 01;8(4)101595, D König, S Savic Prince, S Hayoz, P Zens, S Berezowska, W Jochum, E Stauffer, V Braunersreuther, B Trachsel, S Thierstein, M Mark, S Schmid, A Curioni-Fontecedro, A Addeo, I Opitz, M Guckenberger, M Früh, DC Betticher, HB Ris, R Stupp, SI Rothschild, L Bubendorf, M PlessFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.